MIRA PHARMACEUTICALS, INC. 8-K

What Happened

• On May 21, 2026, MIRA Pharmaceuticals, Inc. entered Amendment No. 1 to its Exclusive License Agreement with MIRALOGX LLC (originally effective November 15, 2023). The Amendment expands the Company’s exclusive licensed territory for Ketamir-2 from the United States, Canada and Mexico to all countries in which patent rights exist and adds international patent filings and applications across multiple jurisdictions. The filing notes the change supports global development and commercialization as MIRA advances Ketamir-2 toward planned Phase 2a development. The Amendment did not materially change the core economic terms of the original license, including royalty obligations.

Key Details

• Amendment effective date: May 21, 2026; press release announcing the Amendment issued May 27, 2026.
• Territory expanded from U.S./Canada/Mexico to all countries where patent rights exist.
• Patent portfolio expanded to include international filings/applications in U.S., Europe, China, Japan, Canada, Australia, India, Israel, Mexico, South Korea, and other jurisdictions.
• Core economic terms (royalties and other financial consideration) were not materially modified.

Why It Matters

• The amendment broadens MIRA’s exclusive rights for Ketamir-2 and expands international patent coverage, which increases the theoretical geographic scope for development and future commercialization.
• Because the core financial terms were not materially changed, the filing does not indicate immediate new royalty burdens or altered payment obligations to MIRALOGX.
• Investors should view this as a strategic step to support global development as the program moves toward Phase 2a; continued progress in clinical development and regulatory milestones will be the primary drivers of value.